Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis

Technology appraisal guidance
Reference number: TA276
Published: 27 March 2013

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Professor Andrew Greening (clinical specialist) nominated by Healthcare Improvement Scotland

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Professor Andrew Greening (clinical specialist) nominated by Healthcare Improvement Scotland

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Professor Andrew Greening (clinical specialist) nominated by Healthcare Improvement Scotland
25 January 2013
(252.39 Kb 13 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 25 January 2013